IA
RNAC icon

IFP Advisors’s Cartesian Therapeutics RNAC Stock Holding History

IFP Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21K Buy
212
+150
+242% +$1.11K ﹤0.01% 4194
2026
Q1 		$381 Buy
+62
New +$442 ﹤0.01% 4485
2025
Q2 		– Sell
-1
Closed -$13 – 5007
2025
Q1 		$13 Hold
1
– – ﹤0.01% 4212
2024
Q4 		$18 Buy
+1
New +$20 ﹤0.01% 4473
2023
Q1 		– Sell
-1,525
Closed -$550K – 4234
2022
Q4 		$550K Sell
1,525
-45
-3% -$1.92K 0.01% 851
2022
Q3 		$566K Buy
1,570
+518
+49% +$28.4K 0.01% 868
2022
Q2 		$379K Hold
1,052
– – 0.01% 963
2022
Q1 		$379K Buy
+1,052
New +$65.8K 0.01% 963

Other funds holding RNAC

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

IFP Advisors's RNAC Position: Q2 2026 in Review

IFP Advisors increased its Cartesian Therapeutics (RNAC) stake by 242% in Q2 2026, buying an estimated $1.11K and bringing the position to 212 shares worth $2.21K. The position accounts for ﹤0.01% of the portfolio, ranked #4194.

IFP Advisors first reported a position in RNAC in Q1 2022 and has held it in 8 quarters since. The position peaked at $566K in Q3 2022. 5 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • IFP Advisors held 212 shares of Cartesian Therapeutics worth $2.21K as of Q2 2026.
  • IFP Advisors bought 150 Cartesian Therapeutics shares in Q2 2026, an estimated $1.11K.
  • Cartesian Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4194 holding.
  • IFP Advisors first reported a position in Cartesian Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • IFP Advisors's Cartesian Therapeutics position peaked at $566K in Q3 2022.
  • 5 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.